Executive Summary · Uncertainty about the Omicron variant and the Fed’s hawkish pivot led to a sharp market decline that began in late November. The correction subsided in mid-December because the Omicron variant appeared to be less virulent than the Delta variant. Also, the FDA approved two at-home anti-viral drugs that can greatly reduce the risk of hospitalization.
The Manley Macro Memo
The Manley Macro Memo
The Manley Macro Memo
Executive Summary · Uncertainty about the Omicron variant and the Fed’s hawkish pivot led to a sharp market decline that began in late November. The correction subsided in mid-December because the Omicron variant appeared to be less virulent than the Delta variant. Also, the FDA approved two at-home anti-viral drugs that can greatly reduce the risk of hospitalization.